Through strong industry cooperation, significant investment, and smart policy backing, API manufacturing may become self-reliant
Expand the scope of the Production-Linked Incentive (PLI) scheme and increase its allocation to cover more pharmaceutical products and raw materials
The project is set to attract significant manufacturing investments of approximately Rs. 10,500 crore and is also projected to create around 1 lakh direct and indirect jobs
The inspection scope had included six separate Biologics manufacturing units comprising of four Drug Substance and two Drug Product manufacturing plants
Capital expenditure expected to moderate to Rs. 5.6 billion in FY2025 from an estimated Rs. 7.6 billion in FY2024
Against targeted investment of Rs. 3,938 crore, investments worth Rs. 4,024 crores have been made under scheme
The inspection scope included 6 separate Biologics manufacturing units comprising 4 Drug Substance and 2 Drug Product manufacturing plants
The company has now received 100% of the incentive owed to the company for the financial year 2022-23 under the PLI scheme
Sadhana Nitro Chem's plant is the second plant in the world to manufacture pAP from Nitrobenzene
PLI scheme envisages manufacturing of 41 Bulk Drugs with a total outlay of Rs. 6,940 cr. during the tenure of the scheme from 2020-21 to 2029-30
Subscribe To Our Newsletter & Stay Updated
